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The Journal of Immunology
LILRB1 Blockade Enhances Bispecific T Cell Engager
Antibody–Induced Tumor Cell Killing by Effector CD8+
T Cells
Aeryon Kim,* Chia-Jung Han,* Ian Driver,† Aleksandra Olow,‡ Andrew K. Sewell,x
Zemin Zhang,{,‖ Wenjun Ouyang,* Jackson G. Egen,* and Xin Yu*
Elicitation of tumor cell killing by CD8+ T cells is an effective therapeutic approach for cancer. In addition to using immune
checkpoint blockade to reinvigorate existing but unresponsive tumor-specific T cells, alternative therapeutic approaches have been
developed, including stimulation of polyclonal T cell cytolytic activity against tumors using bispecific T cell engager (BiTE) molecules
that simultaneously engage the TCR complex and a tumor-associated Ag. BiTE molecules are efficacious against hematologic tumors
and are currently being explored as an immunotherapy for solid tumors. To understand mechanisms regulating BiTE molecule–
mediated CD8+ T cell activity against solid tumors, we sought to define human CD8+ T cell populations that efficiently respond to
BiTE molecule stimulation and identify factors regulating their cytolytic activity. We find that human CD45RA+CCR72 CD8+ T cells
are highly responsive to BiTE molecule stimulation, are enriched in genes associated with cytolytic effector function, and express
multiple unique inhibitory receptors, including leukocyte Ig-like receptor B1 (LILRB1). LILRB1 and programmed cell death protein
1 (PD1) were found to be expressed by distinct CD8+ T cell populations, suggesting different roles in regulating the antitumor
response. Engaging LILRB1 with its ligand HLA-G on tumor cells significantly inhibited BiTE molecule–induced CD8+ T cell
activation. Blockades of LILRB1 and PD1 induced greater CD8+ T cell activation than either treatment alone. Together, our data
suggest that LILRB1 functions as a negative regulator of human CD8+ effector T cells and that blocking LILRB1 represents a unique
strategy to enhance BiTE molecule therapeutic activity against solid tumors. The Journal of Immunology, 2019, 203: 1076–1087.
T
cells, especially Ag-specific cytotoxic T cells, can detect
and eliminate cancer cells through the recognition of
tumor-associated Ags, such as neoantigens. Neoplastic
cells, however, evade immune surveillance through various
mechanisms. For example, tumor-infiltrating T cells often fail
to eliminate cancer because of an immunosuppressive tumor mi-
croenvironment that induces a dysfunctional state, characterized
by the expression of multiple inhibitory receptors such as pro-
grammed cell death protein 1 (PD1), TIM3, and CTLA4, and
designated as exhausted T cells (TEXH). Importantly, Abs targeting
CTLA-4 and PD1 have demonstrated dramatic therapeutic benefit
in various cancer types, correlating with their ability to enhance
effector T cell (TEFF) function (1). However, these immunotherapy
strategies are successful in only a subset of patients. Although
multiple mechanisms likely account for a failure to respond to
immune checkpoint inhibitory therapy, the inherent immunoge-
nicity of a patient’s tumor and corresponding levels of pre-existing
tumor-reactive T cells present at the start of therapy have emerged
as important factors governing the response (2). For instance, pa-
tients with lower mutation burden and/or with scarce T cell infil-
tration in their tumors generally have poor responses to immune
checkpoint inhibitors (3, 4).
Given the potential limitations of immune checkpoint inhibitory
therapy in patients with low pre-existing antitumor immunity, an
alternative promising therapeutic strategy involves mobilizing
polyclonal T cells against tumor cells in an MHC-peptide
presentation-independent manner. Two such clinically successful
approaches include adoptive cell therapy with chimeric Ag receptor
(CAR) T cells (5, 6) and the use of bispecific T cell engager
(BiTE) Ab constructs (7). CAR T therapy involves engineering
autologous T cells to express a chimeric receptor that is capable of
recognizing tumor-associated surface Ag to trigger T cell activa-
tion, whereas BiTE Ab constructs are a novel class of immuno-
therapy molecules engineered to redirect T cells to tumor sites
and induce T cell activation, immune synapse formation, and
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ultimately tumor cell killing, regardless of Ag specificity (5–7).
BiTE molecules contain two fused single-chain variable frag-
ments, with one that binds to CD3 on T cells and the other that
binds to a tumor-associated Ag (7).
Blinatumomab, a CD19/CD3 BiTE Ab construct, is the first BiTE
molecule approved by the U.S. Food and Drug Administration to treat
various hematologic malignancies (8). Although this therapy provides
evidence that BiTE molecules can induce robust tumor cell killing
in humans, the degree to which this activity will translate to the solid
tumor setting is largely unknown. PD1-expressing TEXH represent
a dominant phenotype among solid tumor–infiltrating CD8+ T cells
(1), and PD1 is known to be induced by BiTE molecule treatment
in vitro (9, 10). This suggests that the PD1/programmed death ligand
1 (PDL1) pathway may potentially interfere with BiTE molecule
activity in solid tumors and provides a rationale for combining BiTE
molecules with PD1 inhibitors. However, other CD8+ T cell subsets
beyond TEXH are found within solid tumors (11, 12). Further
dissecting the function of these populations and their ability to re-
spond to BiTE molecule engagement may lead to additional com-
bination therapy approaches aimed at eradicating solid tumors.
The human peripheral blood CD8+ T cell compartment is com-
prised of multiple subsets, often distinguished by their expression of
the naive/memory marker CD45RA and the chemokine receptor
CCR7. CD8+ naive T cells (TN) are CD45RA
+CCR7+, whereas
CD8+ effector memory T cells (TEM) are CD45RA
2CCR7+/2.
Previous studies have demonstrated that CD8+ TEM contribute to
BiTE molecule activity among peripheral blood CD8+ T cell sub-
sets, whereas CD8+ TN show minimal response to BiTE molecule
treatment (13). In addition, blocking PD1 has been shown to mainly
expand the intratumoral effector memory subset of CD8+ T cells in
patients (14). An additional Ag-experienced CD8+ T cell population
is defined as CD45RA+CCR72 (effector memory T cells re-
expressing CD45RA [TEMRA]). These effector cells have high cyto-
toxicity, high sensitivity to apoptosis, low IL-2 production (15), and
represent a significant CD8+ T cell population in elderly individuals
and cancer patients (16, 17). However, the degree to which TEMRA
can efficiently mediate BiTE molecule–induced tumor killing, the
function of these cells within solid tumors, and the mechanisms
regulating their activity, remain largely unknown.
In this study, we studied the phenotype of Ag-experienced CD8+
T cell subsets isolated from human peripheral blood and solid tumor
biopsy specimens, their function following BiTE molecule treat-
ment, and the mechanisms regulating their activity. In blood, we
identify TEMRA as the subset with the most potent cytolytic activity
following BiTE molecule engagement and find that a subset of these
cells expressing high levels of cytolytic effector molecules also
expresses the ITIM-containing inhibitory leukocyte Ig-like receptor
B1 (LILRB1), which can function as a negative regulator of BiTE
molecule–induced tumor cell killing. Importantly, LILRB1 and PD1
showed nonoverlapping expression patterns across CD8+ TEM and
TEMRA subsets, and blocking both pathways synergistically en-
hanced CD8+ T cell function. We extend these data from peripheral
blood to tumor-associated T cell populations, demonstrating similar
phenotypic and functional properties of TEMRA. These data highlight
the potential importance of TEMRA in antitumor immune surveillance
and BiTE molecule–mediated activity against solid tumors and sug-
gest that blockade of LILRB1 may be a promising therapeutic ap-
proach to enhance their cytolytic activity.
Materials and Methods
Abs and flow cytometry
The following Abs were used: CD3 (Sk7; eBioscience), CD4 (OKT4; Bio-
Legend), CD8 (RPA-T8; BD Biosciences), CCR7 (G043H7; BioLegend),
CD45RA (HI100; BioLegend), LILRB1(GHI/75; BioLegend), PD1
(EH12.1; BD Biosciences), CD69 (FN50; BD Biosciences), granzyme B
(GB11; BioLegend) and perforin (B-D48; BioLegend), HLA-G (MEM-G/9;
Thermo Fisher Scientific). LIVE/DEAD Fixable Viability Dye eFluor 506
(eBioscience), or SYTOX Blue (Thermo Fisher Scientific) was included to
mark dead cells. For staining of cell surface proteins, cells were incubated
with appropriate Ab mixtures for 30 min at 4˚C. To determine expression of
intracellular proteins, cells were fixed for 30 min at 4˚C using the Foxp3
Transcription Factor Staining Buffer Set (catalog no. 00-5523-00; Thermo
Fisher Scientific) following the manufacturer’s protocol. Subset cell
population was isolated by cell sorting with a BD FACSAria cytometer
(BD Biosciences). Data acquisition of Ab-stained samples was carried
out on an LSR II (BD Biosciences) and analyzed with FlowJo software
v10.3 (Tree Star).
Primary human cell assays
Human PBMCs from healthy volunteers were obtained after informed
consent and authorized by the Amgen Research Blood Donor Program.
PBMCs were isolated by density gradient centrifugation (Ficoll-Paque
PREMIUM, catalog no. 17-5442-02; GE Healthcare). Cell subsets were
isolated from PBMCs with appropriate magnetic beads following manu-
facturer’s protocol (STEMCELL Technologies) or by cell sorting with a
BD FACSAria cytometer. Isolated human primary lymphocytes were
cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS,
100 U/ml penicillin and streptomycin, and 2-ME (all from Life Technol-
ogies) at 37˚C. PBMCs were stimulated with 10 ng/ml recombinant human
IL-2 (catalog no. 202-IL-010/CF), 10 ng/ml recombinant human IL-15
(catalog no. 247-ILB-025/CF), or 100 ng/ml recombinant human TNF
(catalog no. 210-TA-020/CF) (all from R&D Systems) and then subjected
to flow cytometry analysis. Isolated T cells were activated with plate-
bound anti-CD3 (OKT3, 5 mg/ml; BD Biosciences) plus soluble anti-
CD28 (CD28.2, 2 mg/ml; BD Biosciences). When indicated, 10 mg/ml
recombinant human PDL1 (catalog no. 762506; BioLegend) or the same
amount of human IgG1 isotype control Ab (catalog no. 403501; Bio-
Legend) was added in culture medium. Samples were analyzed by flow
cytometry. Cytokine concentrations were measured in cell culture su-
pernatants 48 h after stimulation with Luminex assay (EMD Millipore,
Billerica, MA).
Human tumor dissociation
All human tumor specimens were collected under Institutional Review
Board approval with appropriate informed consent. In all cases, materials
obtained were surplus to standard clinical practice. Patient identity and
protected health information/identifying information were redacted from
tissues and clinical data. Biopsy specimens were mechanically disrupted
and incubated with 200 mg/ml Liberase TL (catalog no. 5401020001;
Roche) and 20 U/ml DNase I (catalog no. 4716728001; Roche) at 37˚C
for 15 min followed by tissue disaggregation using gentleMACS Octo
Dissociator (Miltenyi Biotec). Cell suspension was then passed through a
70-mm filter twice and washed with DMEM/F12 containing 10% FBS
(Life Technology, Carlsbad, CA).
Cell lines
SK-MEL-2 (SK2; catalog no. HTB-68, SK2; American Type Culture
Collection) and SK-MEL-5 (catalog no. HTB-70, SK5; American Type
Culture Collection) were maintained EMEM (catalog no. 30-2003;
American Type Culture Collection) with 10% FBS and 1% penicillin/
streptomycin. HLA-G–expressing SK2 (SK2.HLA-G) cells with stable
expression of human HLA-G were established by retroviral transduction.
The HLA-G-b2 microglobulin cDNA was inserted into retrovirus vector
pLHCX2 (catalog no. 631503; Clontech) and was cotransfected with
Lipofectamine 3000 (catalog no. L3000001; Thermo Fisher Scientific) into
GP2-293 packaging cells (catalog no. 631458; Clontech) with pVSV-G
(catalog no. 631530; Clontech). Supernatants were collected 48 h after
transfection and filtered. Then, SK2 cells were transduced with a mixture
of viral supernatant with polybrene at 5 mg/ml (catalog no. TR-1003-G;
EMD Millipore). After spin transduction for 1.5 h at 1200 g, 32˚C, fresh
media was added. The human PDL1 cDNA was inserted into expression
vector pcDNA3.1/Zeo(+) and was transfected into parental SK2 cells or
SK2.HLA-G cells with Lipofectamine 3000 (Thermo Fisher Scientific).
PDL1 and HLA-G expression was confirmed by flow cytometry.
MLR
Isolated human total T cells were seeded into round-bottom 96-well plates
(Corning) at 1 3 105 per well together with 2 3 104 irradiated allogeneic
CD11c+ cells. When indicated, 10 mg/ml of anti-PD1 (clone EH12.2H7,
catalog no. 329902; BioLegend) or anti-LILRB1 (clone GHI/75, catalog
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no. 333704; BioLegend) or both Abs were added to the culture. As control,
10 mg/ml of each matched isotype Abs were used as control. Day 5 su-
pernatants were collected, and IFN-g level was determined by ELISA
(catalog no. 550612; BD Biosciences).
Cytotoxicity assay
Sorted CD8+ T cells from healthy donor PBMCs expressing indicated
markers or total CD8+ T cells from non–small cell lung cancer (NSCLC)
biopsy specimens were used as TEFF cells and coincubated with tumor
target cells at 4:1 ratio for the indicated time period. The BiTE molecule in
this assay is CD3/melanoma Ag recognized by T cells 1 (MART-1) BiTE
Ab construct (Amgen). When indicated, 25 mg/ml anti-LILRB1 (clone
GHI/75; BioLegend) or 10 mg/ml of anti-PD1 (clone EH12.2H7; Bio-
Legend) were added in the assay. After the culture, T cells were removed
by washing with warm media, and target cell killing was determined from
measuring the number of viable target cells by adding CellTiter-Glo
(catalog no. G7570; Promega). Luminescence units (measured in relative
light units [RLUs]) were measured by EnVision 2104 multilable reader
(PerkinElmer). Percentage of specific lysis was calculated as follows: %
Specific Cytotoxicity = [1 2 (RLU live target cells + BiTE molecule)/
(mean RLU live target cells 2 BiTE molecule)] 3 100.
Cell culture and cytotoxic function assay of MelanA-specific
Mel-13 CD8+ T cell line
Mel-13 T cells were expanded as described (18). Expanded Mel-13 T cells
(.50% LILRB1+ by flow cytometry) were used as effector cells and
cocultured with SK5 tumor target cells (104 per well) at indicated ratio.
When indicated, anti-LILRB1 (GHI/75, 20 mg/ml) or same amount of
isotype control Ab were added in the culture. After overnight incubation
at 37˚C, T cells were removed by washing the wells with warm media.
Target cell killing was determined by measuring the number of viable
target cells using CellTiter-Glo (Catalog no. G7570; Promega). Lumines-
cence, in RLUs, was measured by an EnVision 2104 Multilabel Reader
(PerkinElmer). Percentage of specific lysis was calculated as follows:
Percentage Specific Cytotoxicity = [1 2 (RLU live target cells + Mel-13)/
(mean RLU live target cells 2 Mel-13)] 3 100.
RNA sequencing
Global transcript expression in CCR7+ and CCR72 CD8+ T cells isolated
from healthy donor PBMCs was assessed by RNA sequencing (RNAseq).
RNAseq was performed on a cDNA library prepared from total RNA
(2 mg; RNA integrity number.9.5) of each sample isolated using mirVana
miRNA Isolation Kits (Ambion, Grand Island, NY) with on-column DN-
ase treatment. Total RNA quality and concentration was determined using
the Bioanalzyer (Agilent Technologies, Santa Clara, CA) and NanoDrop
(Thermo Fisher Scientific, Wilmington, DE). cDNA was prepared using a
modified protocol based on the Illumina Truseq RNA Sample Preparation
Kit (Illumina, San Diego, CA) and the published methods for strand-
specific RNAseq (19, 20). After size selection of libraries (Pippen
Prep; Sage Science, Beverly, MA), dUTP-containing cDNA strands were
destroyed by digestion of USER enzymes (New England Biolabs, Ipswich,
MA) followed by PCR enrichment for introduction of strand specificity.
The enriched cDNA libraries were analyzed in an Agilent Bioanalyser and
quantified by Quant-iT PicoGreen assays (Life Technologies). RNA se-
quencing reads (Illumina HiSeq platform, 75-bp paired end sequencing)
were aligned to human genome build 38 and fragments per kb per million
were sequenced. Fragments per kilobase of transcript per million mapped
reads were determined using Array Suite software (Omicsoft, Cary, NC)
and in-house software. Differential gene expression analysis was per-
formed using DESeq V2 (21). The RNAseq data have been submitted
to National Center for Biotechnology Information Sequence Read
Archive database (https://urldefense.proofpoint.com/v2/url?u=https-
3A__www.ncbi.nlm.nih.gov_sra_PRJNA535519&d=DwICaQ&c=
Sexio4usKrYWFsrnxgjbcQ&r=isDLOdYR9iBOWpfW7BvglA&m=
2FGyR3rJtIJMf51upHaeB-XYgRM7_qjfjweuZN6liT0&s=suTXFXS5v_
GXcmv4Ba1ju_LXZLZvdLsJKTVkmSHCdwc&e=) under the accession
number PRJNA535519.
Single-cell RNA sequencing
Fresh human CD8+ T cells were sorted into LILRB1+ CCR72 CD45RA+,
LILRB12 CCR72CD45RA+/2, and LILRB12 CCR7+ CD45RA+ subsets
on a BD FACSAria (BD Biosciences) to purity .95%. Each sorted cell
subset was loaded on the 103 Chromium System (22), and single-cell
RNAseq libraries were generated according to the manufacturer’s in-
structions. Sequencing was conducted on a HiSeq 4000 (sequencing
performed by GENEWIZ). Each pooled sample was run in its own lane
according to the 103 39 v2 Chemistry protocol. The Cell Ranger command
line tools (103 Genomics v2.0.0) mkfastq script was used to convert each
Illumina BCL file to FASTQ. Paired FASTQ files for each pooled sample
(1 Lane) were aligned to GRCh38 human genome (v. 1.2.0 from 103
Genomics) using cellranger count script with default settings. The three
CD8+ samples were then aggregated using cellranger aggr script. Using
the R software package, Monocle (v2.6.1) data were transformed from
raw unique molecular identifiers to normalized counts using Monocle’s
negbinomial.size (23) model. Cells were classified by expression of each
respective gene (LILRB1, CCR7), positive if expression .1 and negative
if expression,1. The classifyCells function in Monocle was used to create
the cell classification labels. The q value and p value statistics, along with
fold change, were computed across the three cell classifications. Genes
with a q value ,0.04 were kept. The mean expression of each gene was
computed and the top 50 genes by fold change across each pairwise group
were kept. The heatmap was created from mean expression values in each
group using the python package seaborn “clustermap” function. Gene
averages are z-scores across each gene (mean of 0 and variance of 1).
Single-cell RNAseq data visualization
All visualizations are created using R programming language (24) using
ggplot2 and ggbeeswarm visualization packages (25, 26). Statistics were
computed using function from ggpubr package (27). Each swarm plot
(gene expression per cluster across cells) visualizes a single gene by
custom cluster assignment with gene expression values represented as
binary log plus + 0.1. Previously determined and published clusters for
corresponding datasets (11, 12) were used to define clusters: TEM (hepa-
tocellular carcinoma: CD8_Cluster5-GZMK; NSCLC: CD8_C4-GZMK);
TEFF (hepatocellular carcinoma: CD8_Cluster2-CX3CR1; NSCLC:
CD8_C3-CX3CR1); and TEXH (hepatocellular carcinoma: CD8_Cluster4-
LAYN; NSCLC: CD8_C6-LAYN). Boxplots visualize five summary sta-
tistics (the median, two hinges, and two whiskers) and are overlaid with
swarm plots of cells roughly representing the density distribution of the
data points along the gene expression values. A nonparametric Kruskal–
Wallis test was used to test for difference in gene expression of each gene
between clusters, followed by pairwise Wilxocon rank sum test pairwise
comparisons. The p values were adjusted using Benjamini–Hochberg
procedure. For per patient boxplot, gene expression (log2(transcripts per
million + 0.1)), as measured from previously published NSCLC datasets
(12), was averaged per patient for each depicted gene (NSCLC npatients =
14). For gene expression of each gene between clusters, an ANOVA was
used to analyze the differences among group means, followed by pairwise
t test comparisons. The p values were adjusted using Benjamini–Hochberg
procedure. Statistical plots were generated with GraphPad Prism software,
and a two-sided paired or nonpaired Student t test was used to obtain
p values. Sample sizes were determined based on experimental data dis-
tribution pattern.
Results
LILRB1-expressing effector CD8+ T cells can efficiently
mediate BiTE molecule–induced cytolytic activity
To understand which human CD8+ T cell subset most efficiently
mediates BiTE molecule–induced T cell–dependent cellular cytotox-
icity, we isolated human CD8+ TN, TEM, and TEMRA subsets from
peripheral blood based on expression of surface markers CD45RA and
CCR7 (15). The cytolytic activity of isolated CD8+ T cell subsets was
determined using SK2 cells endogenously expressing the MART-1
tumor Ag and a MART-1–specific BiTE molecule. As shown in
Fig. 1A, TEMRA were the most potent at BiTE molecule–induced
killing of target cancer cells (EC50 = 25.51 pM), followed by
CD45RA2CCR72 TEM (EC50 = 58.11 pM) and CD45RA
+CCR7+ TN
(EC50 = 7948 pM). TEMRA also had the highest maximum percentage
of tumor cell lysis (Fig. 1A). These data suggest that enhancing the
effector function of TEMRA may further enhance BiTE molecule–
mediated tumor killing.
To identify regulatory pathways that modulate CTL activity,
we evaluated the gene transcriptional profiles of sorted TN, TEM,
central memory T cell (TCM) and TEMRA subsets. Differential
expression analysis comparing CCR7+ TN and TCM with CCR7
2
TEM and TEMRA populations revealed expression of various genes
associated with CD8+ T cell function, including PRF1, GZMB,
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and CX3CR1 (Fig. 1B, Supplemental Table I). In addition, LILRB1,
an ITIM-containing inhibitory receptor that signals downstream of
interactions with HLA-G and several classical MHC class I alleles
(28), was also found to be highly expressed by the TEMRA and TEM
populations (Fig. 1B, Supplemental Table I), with preferential ex-
pression in TEMRA (Fig. 1C). Analysis of CD8
+ T cell phenotypes
by flow cytometry confirmed that the majority of TEMRA but only a
small population of TEM express LILRB1 (Fig. 1D, 1E).
LILRB1 is a marker of CD8+ T cell with potent
effector function
The above data suggested that LILRB1 expression may be asso-
ciated with acquisition of CD8+ T cell effector function. Indeed,
ex vivo FACS analysis of peripheral blood T cells from multiple
donors confirmed that the majority of CD8+LILRB1+ T cells
constitutively express perforin and granzyme B (Fig. 2A),
whereas very few perforin- or granzyme B–expressing cells are
found in LILRB12 TEMRA and CD8
+ TEM (Fig. 2B). Expression
of effector molecules by LILRB1+CCR72, LILRB12CCR72, and
LILRB12CCR7+ CD8+ T cell subsets was also evaluated in super-
natants from cultured-sorted T cells either without (Fig. 2C) or with
(Fig. 2D) activation. In the absence of stimulation, LILRB1+CCR72
T cells were found to secrete perforin and granzyme B to a greater
extent than the other two subsets, consistent with the above FACS
data. In contrast, upon TCR activation, both LILRB1+CCR72 and
LILRB12CCR72 T cells were induced to produce an equal amount
of granzyme B and IFN-g; however, the LILRB1+ subset still pro-
duced higher quantities of perforin compared with the LILRB12
population (Fig. 2D). Interestingly, LILRB1+CCR72 cells produced
minimal amounts of IL-2 relative to the LILRB12CCR72 subset.
Finally, single-cell RNAseq was used to further characterize total
transcripts in sorted CD8+ LILRB1+ and LILRB12 T cell subsets. We
found that LILRB1+ cells show preferential expression of multiple
genes known to be associated with TEFF, including GNLY, PRF1,
GZMB, and KLRD1 (Fig. 2E), further supporting the finding that
LILRB1 is a marker of an effector CD8+ T cell population.
FIGURE 1. CD8+ TEMRA show potent BiTE molecule–mediated tumor cell killing and preferentially express the LILRB1 inhibitory receptor. (A) Human
CD8+ T cells from healthy donors were sorted into TN, TEM, and TEMRA subsets and incubated with SK2 tumor cells in the presence of indicated amount of
MART-1–specific BiTE molecule. Specific cytotoxicity was determined after 45 h. Results (mean 6 SEM) are shown from four independent experiments
using three healthy donors as the source of CD8+ T cells. (B) Volcano plot showing differentially expressed genes between CCR72 and CCR7+ human
CD8+ T cells with p value,0.05 and fold change.24 (red lines). (C) Box plot showing LILRB1 mRNA expression of RNAseq analysis of TN, TCM, TEM,
and TEMRA subsets of CD8
+ T cells (n = 2–6 individual donor samples per cell type). (D) Representative FACS plots showing preferential LILRB1 ex-
pression on the surface of CD8+ TEMRA. (E) Quantitation of LILRB1 expression in indicated CD8
+ subsets determined by FACS analysis across multiple
donors (n = 8). *p , 0.05, **p , 0.01, paired Student t test.
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LILRB1 inhibits BiTE molecule–mediated CD8+ T cell
effector function
LILRB1 has been previously shown to negatively regulate the function
of NK and CD8+ T cells (29, 30). Mel-13 is a cytolytic CD8+ T cell
line that is specific for HLA A*0201 (HLA-A2)–restricted Melan-A
(also known as MART-1)–derived epitope and may lyse melanoma
tumor cells (18). These cells upregulated LILRB1 expression upon
expansion with appropriate feeder cells (Fig. 3A). Blocking LILRB1
significantly enhanced Mel-13 CD8+ T cell cytolytic activity of SK-
MEL-5 (HLA-A2+) melanoma cells (Fig. 3B). These data suggest
FIGURE 2. LILRB1 marks CD8+ cells with higher effector molecule expression. (A) Representative dot plots show LILRB1 coexpression with perforin
(left panel) and granzyme B (GZMB, right panel) in gated CD8+ T cell by ex vivo FACS analysis. (B) Quantitation of perforin (left panel) and GZMB (right
panel) expression in LILRB12CCR72 and LILRB1+CCR72 CD8+ subsets from multiple donors (n = 4). (C and D) Human CD8+ T cells from each donor
were sorted into three subsets based on LILRB1 and CCR7 expression. Quantitation of effector molecules in supernatants were performed using a Luminex
assay from resting (C) and TCR-activated (D) CD8+ T cell subsets after 48 h (n = 6). (E) Single-cell RNAseq results show differential gene expression
between LILRB1+ and LILRB12 memory CD8+ T cells. *p , 0.05, paired Student t test.
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FIGURE 3. LILRB1 inhibits cytotoxic CD8+ T cell effector function in vitro. (A) Representative dot plot shows LILRB1 expression on expanded Mel-13
cytolytic CD8+ T cells. (B) In vitro Ag-specific CTL cytotoxicity assay with expanded Mel-13 cytolytic CD8+ T cells as effector cells and SK5 cells as
target cells. Indicated ratio of effector cells and target cells were coincubated for 20 h in the presence of anti-LILRB1 blocking Ab (open squares) or isotype
control Ab (filled circles). Results shown as mean 6 SD of triplicate wells for each indicated ratio, and data are a representative of three independent
experiments. (C) Representative histogram for HLA-G expression on SK2 cells (dotted line) and HLA-G–transfected SK2 cells (SK2.HLA-G, solid line)
analyzed by FACS. Gray-filled histogram represents isotype control. (D) Representative FACS plots to show gating strategy for CD8+ TEMRA sorting from
healthy donor PBMCs (left panel) and LILRB1 expression on sorted TEMRA (right panel). (E) BiTE molecule–mediated cytotoxicity of isolated CD8
+
TEMRA to indicated target cells in the presence of anti-LILRB1 blocking Ab (filled bars) or isotype control Ab (open bars). T cell and tumor cell coculture
with no BiTE Ab construct was used as baseline for specific lysis calculation. Results shown as mean 6 SEM of T cells isolated from three donors (n = 3).
(F) Representative histograms for CD69 expression on TEMRA cocultured with SK2 cells (line histograms) or SK2.HLA-G cells (gray-filled histograms) for
45 h in the presence of 0.4 nM BiTE molecule (right panel) or without BiTE molecule (left panel). (G) Isolated CD8+ TEMRAwere cocultured with indicated
tumor cells for 18 (left panel) or 45 h (right panel) in the presence of 0.4 nM BiTE molecule. Percentage of CD69+ cells (mean 6 SD) were determined by
FACS analysis. Data are representative of three independent experiments with two individual donors as T cell source. (H) (Figure legend continues)
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that LILRB1 may function to inhibit CTL effector function and
their ability to kill tumor cells. To determine if LILRB1 can
regulate the function of CD8+ TEFF following stimulation with
BiTE molecules, we performed a CD8+ T cell–mediated tumor
cell–killing assay using SK2 target cells engineered to express
HLA-G, the ligand for LILRB1, and a MART-1–specific BiTE
molecule (Fig. 3C). TEMRA were enriched from healthy donor
PBMCs by flow sorting (Fig. 3D) and were cocultured with pa-
rental SK2 cells or SK2.HLA-G cells in the presence of anti-
LILRB1– blocking or control Abs. TEFF function was induced by
a suboptimal concentration of the MART-1 BiTE molecule and
measured as specific target cell lysis. These data demonstrate that
HLA-G expression on target cells can dramatically reduce BiTE
molecule–mediated T cell cytolytic activity and that this effect is
reversed by LILRB1 blockade (Fig. 3E). The presence of HLA-G
on tumor cells also significantly inhibited BiTE molecule–
mediated upregulation of CD69 on effector CD8+ T cells
(Fig. 3F, 3G). These data indicate that LILRB1 functions as
a negative regulator of CD8+ T cell effector function and that
blocking LILRB1 can be used to enhance BiTE molecule–
mediated tumor cell killing.
We next wanted to confirm that LILRB1 was capable of
inhibiting tumor-associated CD8+ T cells similar to its effect on
T cells derived from peripheral blood of health donors. We
isolated tumor-infiltrating CD8+ T cells from NSCLC biopsy
specimens and evaluated their activity against SK2 and
SK2.HLA-G target cells upon treatment with a MART-1–specific
BiTE Ab construct. We found that the presence of HLA-G on the
target cell significantly inhibits BiTE molecule–induced T cell
activation (Fig. 3H) and cytolytic activity (Fig. 3I). Inhibition of
cytolytic activity can be restored with LILRB1 blockade
(Fig. 3I). These results demonstrate that LILRB1 can function as
an immune checkpoint inhibitory receptor for tumor-infiltrating
CD8+ TEFF and suggests that blocking LILRB1 may enhance
BiTE molecule–mediated tumor CD8+ T cell cytolytic activity in
patients.
Differential regulation of LILRB1 and PD1 expression in
CD8+ T cells
PD1 is known to exert potent repressive activity on tumor-
infiltrating CD8+ T cells, and therapeutic Abs blocking the PD1
pathway can significantly enhance T cell effector function, pro-
viding therapeutic benefit in multiple cancers (31). Given the
finding that LILRB1 can also function as negative regulator of
CD8+ T cell function, we examined the regulation of LILRB1 and
PD1 expression on total CD8+ T cells. We first examined LILRB1
and PD1 expression downstream of TCR signaling, confirming
that PD1 is rapidly upregulated upon T cell activation. In contrast,
LILRB1 expression was not sensitive to TCR signaling (Fig. 4A,
4B). As blocking the PD1 pathway has been shown to further
promote effector function of CD8+ T cells (31, 32), we next ex-
amined whether LILRB1 expression can be regulated by PD1
signaling. Activation of CD8+ TEM in the presence of PD1
blockade resulted in an increase in the frequency of LILRB1+
effector cells, whereas the expression of PD1 was not significantly
altered (Fig. 4C, 4D). Furthermore, cytokines known to promote
CD8+ T cell effector differentiation and function, such as IL-2 and
IL-15 but not TNF-a, also significantly increased the frequency
of LILRB1+ T cells (Fig. 4E, 4F). Thus, signals that enhance
CD8+ T cell effector function but not TCR activation alone can
promote differentiation of LILRB1+ TEFF.
PD1 is preferentially upregulated on LILRB12 CD8+ T cells
Given our findings that PD1 but not LILRB1 is upregulated on
CD8+ T cells upon TCR activation, we next asked whether there
is a difference in the expression of PD1 on either LILRB1+ or
LILRB12 CD8+ T cell subsets. Upon TCR stimulation, PD1 ex-
pression was found to be preferentially upregulated on LILRB12
CD8+ T cells isolated from peripheral blood (Fig. 5A). These data
suggest that LILRB1+ T cells represent a unique population that
may not be subject to regulation by the PD1 pathway. To extend
these data to tumor-associated T cells, we analyzed publicly
available single–T cell RNAseq data from hepatocellular carcinoma
(11) and NSCLC (12). In both datasets, LILRB1 and PDCD1
showed mutually exclusive expression patterns in tumor CD8+
T cells (Fig. 5B–D). In contrast, expression patterns of other in-
hibitory receptor genes, such as HAVCR2 and CTLA-4, were largely
overlapping with PDCD1 (Fig. 5B, 5C). Notably, expression levels
of another HLA-G receptor KIR2DL4 (33) (Fig.5B, 5C), as well as
many other NK cell receptors (NKR) (e.g., KLRC1 and KIRs, data
not shown), are low and/or less frequent in effector CD8+ T cell
clusters in tumor.
We also evaluated PD1 and LILRB1 expression by flow
cytometry on CD8+ T cells isolated from additional NSCLC
biopsy specimens. PD1 and LILRB1 showed a heterogenous
pattern of expression across tumor samples, with some samples
having CD8+ T cells predominantly expressing either PD1 or
LILRB1 and others having similar frequencies of LILRB1+ or
PD1+ CD8+ T cells (Fig. 5E, 5F). Nevertheless, in all the cases
we examined, PD1 and LILRB1 showed a mutually exclusive
expression pattern consistent with data from healthy donor
T cells. Importantly, LILRB1+ CD8+ T cells represented a
dominant phenotype in 4 out of 11 NSCLC tumors (Fig. 5F),
suggesting that across patients, different inhibitory mecha-
nisms may function to preferentially restrict antitumor T cell
responses.
LILRB1 and PD1 have independent roles in restricting
CD8+ TEFF function
Given the finding that LILRB1 and PD1 are expressed on different
populations of CD8+ T cells and that PD1 blockade may promote
differentiation of LILRB1+ T cells, we hypothesized that simul-
taneous blockade of LILRB1 and PD1 could lead to greater T cell
activation than blockade of either pathway alone. To test this
hypothesis, we engineered SK2 tumor cell lines stably expressing
PDL1 (SK2.PDL1), HLA-G (SK2.HLA-G), or both molecules
(SK2.PG) (Fig. 6A). CCR72 CD8+ TEFF containing both
LILRB1+ TEMRA and PD1
+ TEM were enriched from healthy do-
nor PBMCs by flow sorting (Fig. 6B). As expected, target cells
expressing both HLA-G and PDL1 are more resistant to BiTE
molecule–induced CCR72 CD8+ T cell cytolytic activity than
parental SK2 cells or SK2 cells expressing either PDL1 or HLA-G
alone (Fig. 6C). Consistent with these data, only the combination
of anti-PD1 and anti-LILRB1 was able to fully restore CTL
Isolated tumor-associated CD8+ T cells were added to SK2 or SK2.HLA-G cells and treated with a MART-1–specific BiTE molecule for 45 h. Expression of
CD69 measured as mean florescence intensity (MFI) on CD8+ T cells was determined by FACS analysis. Each type of symbol represents data obtained from
an individual donor with mean 6 SEM shown. (I) BiTE molecule–mediated cytotoxicity of isolated tumor CD8+ T cells to indicated target cells in the
presence of anti-LILRB1 blocking Ab (gray-filled bars) or isotype control Ab (open bars). Each type of symbol represents data obtained from an individual
donor with mean 6 SEM shown. *p , 0.05, **p , 0.01, paired Student t test. ns, not significant.
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effector cell–killing activity against SK2.PG tumor cells expressing
both HLA-G and PDL1 (Fig. 6D–G).
In addition, evaluating the role of LILRB1 and PD1 in BiTE
molecule–mediated T cell activation assays, we also performed
MLR assays, comparing the effects of anti-LILRB1 or anti-PD1
alone and in combination on T cell activation. We found that
the combination of anti-PD1 and anti-LILRB1 blockade leads
to significantly increased IFN-g production compared with either
FIGURE 4. LILRB1 expression on CD8+ T cell surface is upregulated by effector cytokines and anti-PD1 blockade. (A) FACS analysis of LILRB1 (left
panel) and PD1 (right panel) expression on the surface of CD8+ T cells upon TCR activation (solid lines). Gray-filled histograms are control CD8+ T cells
without stimulation. (B) Quantitation of the results from (A) across multiple donors (n = 5). (C) Purified human CD8+ TEM cells were activated with anti-
CD3 plus anti-CD28 in the presence of 10 mg/ml recombinant human PDL1 (rhuPDL1, solid lines) or human IgG1 (control, dashed lines). After 48 h,
LILRB1 (left panel) and PD1 (right panel) expression was determined by FACS analysis. Gray-filled histograms are isotype staining controls. (D)
Quantitation results of (C) across multiple donors (n = 3). Representative data shown as mean 6 SD. (E) Human PBMCs were stimulated with rIL-2, IL-15,
or TNF for 48 h (solid lines) and subjected to FACS analysis. Gray-filled histograms represent CD8+ T cells gated from unstimulated PBMCs. (F)
Quantitation of (E) across multiple donors (n = 5). *p , 0.05, Student t test. ns, not significant.
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treatment alone (Fig. 6H, 6I). Taken together, these data indicate
that LILRB1 functions as an inhibitory receptor for a unique
population of PD12 TEFF and suggest that the combination of
LILRB1 and PD1 blockade may be required to mobilize the full
complement of tumor-associated CD8+ T cells to participate in the
antitumor response.
Discussion
BiTE molecules have been shown to activate CD8+ T cells and
enhance CTL function in vitro and in vivo (34). The BiTE Ab
construct showed translating to inhibition of solid tumor growth in
preclinical mouse models (35). However, the ability of BiTE
molecules to effectively treat solid tumors in patients is still under
evaluation. Major challenges associated with applying BiTE
molecules to the treatment of solid tumors are the suppressive
tumor microenvironment and the expression of multiple check-
point inhibitory receptors by tumor-associated T cells that func-
tion to reduce BiTE molecule activity and thus limit their
therapeutic efficacy. For example, the PD1 pathway and the
presence of TGF-b or IL-10 can reduce BiTE molecule–mediated
CD8+ cytolytic T cell–killing activity in vitro (35, 36). Identifying
additional regulatory pathways capable of restricting CD8+ T cell
FIGURE 5. LILRB1 and PD1 are expressed by distinct CD8+ T cell subsets in tumor. (A) Representative FACS plot to show LILRB1 and PD1 expression
on TCR-activated human CD8+ T cells. Percentage of cells in each quadrant is indicated. (B and C) Single-cell RNAseq swarm plots showing the expression
of indicated genes in tumor-infiltrated CD8+ T cell clusters isolated from NSCLC (B) or hepatocellular carcinoma (C). (D) Boxplots of LILRB1 and PD1
gene expression in tumor-infiltrated CD8+ T cell clusters from NSCLC patients. Each dot represents average gene expression from a given patient.
****p , 0.0001, paired Student t test. (E) Representative FACS plots to show LILRB1 and PD1 expression on tumor-infiltrating CD8+ T cells. Numbers
represent percentage of cells in a given quadrant. (F) Quantitation of (E) from 11 NSCLC tumor patients. Percentage of total tumor CD8+ T cells expressing
LILRB1 (in red), PD1 (in blue), or both (in gray) in each tumor.
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FIGURE 6. Anti-LILRB1 synergize with anti-PD1 to promote CD8+ T cell effector function. (A) Dot plots to show HLA-G and PDL1 expression on established tumor
cells lines. (B) Representative FACS plots to show gating strategy for CCR72 CD8+ T cell sorting from healthy donor PBMCs (left panel) and LILRB1 and PD1 ex-
pression on sorted CCR72CD8+ T cells (right panel). (C) Sorted CCR72CD8+ T cells were incubated with indicated tumor cells in the presence of indicated amount of
MART-1–specific BiTE molecule. Specific cytotoxicity was determined after 45 h. Results shown as mean6SD from triplicated wells and are a representative from three
independent experiments using two healthy donors as the source of CD8+ T cells. Numbers are maximum percentage of specific lysis. (D–F) BiTE molecule–mediated
cytotoxicity of isolated CCR72CD8+ T cells to indicated target cells in the presence of anti-LILRB1 blocking Ab (light gray bars), anti-PD1 blocking Ab (dark gray bars),
combination of anti-LILRB1 and anti-PD1 (black bars), or isotype control Ab (open bars). T cell and tumor cells coculture with no BiTE Ab construct was used as baseline
for specific lysis calculation. Percentage of specific lysis (D), T cell activation represented by CD69 upregulation measured by FACS (E), and perforin production by
Luminex (F) was determined and plotted. Results shown as mean 6 SD of triplicated wells. Data are a representative of three independent experiments using T cells
isolated from two donors. (G) Quantitation of anti-LILRB1 plus anti-PD1 in promoting CCR72CD8+ T cell cytolytic activity. Each dot represents data obtained from an
individual donor. *p, 0.05, paired Student t test. (H and I) Isolated total T cells were cocultured with allogeneic CD11c+ cells in the presence of indicated Abs. After 5 d,
culture supernatants were collected, and IFN-g levels were determined by ELISA. Data are plotted as mean 6 SD. Results is representative of three independent ex-
periments with T cells from two individual donors and CD11c+ cells from three individual donors. *p , 0.05, **p , 0.01, Student t test.
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function is critical for our ability to unlock the full potential of
BiTE molecule therapies and other T cell–targeted approaches in
solid tumors.
In this study we identify LILRB1 as a novel checkpoint in-
hibitory molecule capable of restricting BiTE molecule–mediated
CD8+ T cell effector function. Given the following factors: 1)
LILRB1 is highly expressed by the CD8+ TEMRA subset, which
is the most potent population for BiTE molecule–induced toxicity,
2) LILRB1–expressing CD8+ T cells infiltrate solid tumors, 3)
HLA-G overexpression has been reported in many solid tumors,
and its expression is positively associated with poor prognosis
(37), and 4) LILRB1 blockade increases CD8+ T cell cytolytic
activity in vitro, these findings suggest that blocking LILRB1 may
enhance BiTE molecule–mediated efficacy against solid tumors.
Blocking LILRB1 may be especially important in the context of
HLA-G+ solid tumors, in which LILRB1-mediated inhibitory
signals may be a dominant mechanism restricting cytolytic CD8+
T cell effector function. Similar to previous observations (38), we
find that LILRB1 is coexpressed with perforin and granzyme B
in human CD8+ T cells. We extend these findings by performing
RNAseq analysis on CD8+ T cells that were sorted based on
LILRB1 expression, demonstrating that LILRB1+ CD8+ T cells
preferentially express multiple effector molecules beyond perforin
and granzymes. These data suggest functional specialization of
the LILRB1+ T cell subset for cytolytic activity, a hypothesis
consistent with findings from our BiTE molecule–mediated cy-
totoxicity studies. In addition to marking effector CD8+ T cells
with potent cytolytic activity, we also demonstrate that LILRB1
functions as an immune checkpoint receptor, effectively inhibiting
both Ag-specific CTL cytolytic activity and BiTE molecule–
induced polyclonal activation of effector CD8+ T cells.
Importantly, we find that LILRB1 and PD1 are preferentially
expressed by distinct CD8+ T cell subsets in both tumor tissue
and in healthy donor blood. The nonoverlapping expression of
LILRB1 and PD1 in tumor-infiltrating CD8+ T cells is also ob-
served by single-cell RNAseq analysis in multiple tumor types,
including hepatocellular carcinoma (11), NSCLC (12), and colo-
rectal cancer (39). Although many well-studied inhibitory recep-
tors, such as TIM3 and CTLA-4, are coexpressed with PD1 on
CD8+ TEXH in tumor, LILRB1
+ CD8+ T cells are largely devoid of
these inhibitory receptors. These data suggest that LILRB1+ cells
are not subject to the same regulatory pathways as TEXH. Previous
studies have demonstrated that NKR, such as KLRG-1, KLRC-1,
and KIRs, are upregulated during CD8+ T cell differentiation to-
ward an effector phenotype. Further analysis of published single-
cell RNAseq data demonstrated that these NKRs either have low
expression levels on very few CD8+ T cells, such as many KIRs,
or their expression is largely not overlapping with LILRB1, such
as KLRC-1. These findings suggest that LILRB1 is unique in
terms of its expression and function on CD8+ T cells.
The regulation of LILRB1 gene expression is largely unknown
(40). We find that cytokines that promote T cell effector function
(such as IL-2 and IL-15) but not proinflammatory cytokines, such
as TNF-a, increase LILRB1 expression. Interestingly, blocking
PD1 also enhances LILRB1 expression, possibly because of in-
creased IL-2 production by T cells upon PD1 blockade. Interest-
ingly, expression of KLRG-1, another inhibitory receptor that is
highly expressed by subsets of effector CD8+ T cells, is also up-
regulated by IL-2 (41). Thus, LILRB1 upregulation may serve as a
negative feedback regulator for effector CD8+ T cells in response
to signals that boost CD8+ T cell effector function. An implication
of these data is that blocking LILRB1 will be additive/synergistic
with PD1 blockade both by virtue of the ability of this therapeutic
combination to activate two different CD8+ T cell subsets and the
potential for anti-PD1/PDL1 therapy to increase differentiation
and accumulation of LILRB1+ effector T cells, whose activity
would be potentiated by anti-LILRB1.
Our study identifies LILRB1 as an inhibitory pathway that is
highly differentiated from current immune checkpoint inhibitor
combinations and has clear relevance as a therapeutic target capable
of enhancing the efficacy BiTE molecules or other T cell–targeted
approaches that are currently undergoing clinical evaluation.
Moreover, our findings also generate, to our knowledge, new
hypotheses beyond BiTE Ab construct therapy, suggesting that
further characterization of T cell heterogeneity in tumors with
respect to function and expression of inhibitory pathways may
identify orthogonal mechanisms regulating distinct aspects of
the antitumor T cell response, thus representing attractive targets
for combination therapy approaches.
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Kim, A., C.-J. Han, I. Driver, A. Olow, A. K. Sewell, Z. Zhang, W. Ouyang, J. G. Egen, and X. Yu. 2019. LILRB1 blockade enhances
bispecific T cell engager antibody–induced tumor cell killing by effector CD81 T cells. J. Immunol. 203: 1076–1087.
Because of errors in the preparation of Fig. 5, several of the swarm plots from Fig. 5B were inadvertently duplicated in Fig. 5C. The
corrected figure is shown below. The figure legend was correct as published and is shown below for reference. Fig. 5 also has been
corrected in the online version of the article, which now differs from the print version as originally published.
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FIGURE 5. LILRB1 and PD1 are expressed by distinct CD81 T cell subsets in tumor. (A) Representative FACS plot to show LILRB1 and PD1 ex-
pression on TCR-activated human CD81 T cells. Percentage of cells in each quadrant is indicated. (B and C) Single-cell RNAseq swarm plots showing the
expression of indicated genes in tumor-infiltrated CD81 T cell clusters isolated from NSCLC (B) or hepatocellular carcinoma (C). (D) Boxplots of LILRB1
and PD1 gene expression in tumor-infiltrated CD81 T cell clusters from NSCLC patients. Each dot represents average gene expression from a given patient.
****p , 0.0001, paired Student t test. (E) Representative FACS plots to show LILRB1 and PD1 expression on tumor-infiltrating CD81 T cells. Numbers
represent percentage of cells in a given quadrant. (F) Quantitation of (E) from 11 NSCLC tumor patients. Percentage of total tumor CD81 T cells expressing
LILRB1 (in red), PD1 (in blue), or both (in gray) in each tumor.
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